Jacksonville, FL Clinical Trials Report — May 2026

For Jacksonville residents considering participation in clinical research, May 2026 brings a mix of urgent opportunities and significant new studies. With 57 trials slated to close within the next 90 days, prompt action is essential for those interested in contributing to medical advancements before enrollment windows close.

Among these rapidly closing studies, 10 are still actively seeking healthy volunteers, offering a chance for individuals without specific health conditions to participate. These opportunities are particularly time-sensitive, as new trials this month do not include options for healthy volunteers.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also have limited time to join research. Trials focused on various neurological conditions, cardiovascular issues, and cancer are among those with impending deadlines for enrollment. Conditions with trials closing soon include:

• Stroke (3 trials)
• Amyotrophic Lateral Sclerosis (2 trials)
• Intracranial Aneurysm (2 trials)
• Advanced Breast Cancer (1 trial)
• Alzheimer's Disease (1 trial)
• Alzheimer Disease (1 trial)
• Airway Management (1 trial)
• Amputees (1 trial)
• Anxiety (1 trial)
• Arthropathy of Hip (1 trial)

New Research Opportunities Emerge in Jacksonville

This month, Jacksonville saw the opening of 12 new clinical trials, matching the number of trials launched in April 2026. This brings the total number of actively recruiting clinical trials in Jacksonville, FL, to 854 across 296 research facilities, highlighting the city's active role in medical research.

May brings several high-profile new trials to Jacksonville, including significant Phase 2 and 3 studies from major sponsors like Novo Nordisk A/S, Eli Lilly and Company, and AstraZeneca. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Another Phase 3 study from Novo Nordisk A/S, NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight," is seeking 2,500 participants to test the effectiveness and safety of CagriSema for body weight loss.
• Eli Lilly and Company is sponsoring NCT07602582, a Phase 3 "Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)." This study, with 550 participants, aims to determine if annual doses of donanemab provide clinical benefit to participants who previously took the drug.
• Also from Eli Lilly and Company, NCT07589595 is a Phase 2 "Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)." This trial, involving 350 participants, evaluates whether donanemab treatment slows the progression of cognitive and functional decline.
• AstraZeneca is sponsoring NCT07608354, a Phase 2 "Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM." This study, with 326 participants, investigates a combination therapy for Transthyretin-mediated amyloid cardiomyopathy.
• A Phase 3 study from Eli Lilly and Company, NCT07613294, "A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk," is seeking 252 participants to investigate how lepodisiran affects plaque in coronary arteries.

New trials this month are exploring a range of conditions, with the most frequent being obesity (3 trials), followed by conditions related to amputation (3 trials across various specific types), amyloid (1 trial), aortic aneurysm (1 trial), aphasia (1 trial), apraxia of speech (1 trial), atherosclerosis (1 trial), and cardiovascular diseases (1 trial). Of the 12 new trials, 9 are drug trials, 3 are device trials, 2 are biological studies, and 1 is another type of study. Industry sponsors are leading the majority of new research, with 9 new trials from industry compared to 3 from other sources.

Jacksonville's Leading Research Facilities

Jacksonville is home to prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Mayo Clinic in Florida (161 trials)
• Mayo Clinic (69 trials)
• Mayo Clinic Florida (63 trials)
• Research Site (41 trials)
• Mayo Clinic Jacksonville (41 trials)
• Nemours Children's Clinic-Jacksonville (30 trials)
• Baptist MD Anderson Cancer Center (21 trials)
• Jacksonville Center for Clinical Research (20 trials)
• Mayo Clinic - Jacksonville (13 trials)
• University of Florida (12 trials)
• Cancer Specialists of North Florida (11 trials)
• Nemours Children's Health (9 trials)

The Mayo Clinic system, with its various designations, clearly dominates the research landscape in Jacksonville, offering a broad spectrum of studies. Facilities like Baptist MD Anderson Cancer Center specialize in oncology, while Nemours Children's Clinic-Jacksonville and Nemours Children's Health focus on pediatric research.

Participation Details and Nearby Options

Participation in clinical trials is open to a diverse range of individuals. Of the 12 new trials launched this month, all 12 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. However, none of the new trials this month include children, nor are any female-only or male-only. While 0 of the new trials accept healthy volunteers, there are still 58 total trials currently recruiting healthy participants across Jacksonville, including the 10 urgent opportunities closing soon.

For those looking to broaden their search beyond Jacksonville, other cities in Florida offer additional clinical trial opportunities. Nearby cities with active trials include Miami (23 trials), Tampa (9 trials), Orlando (9 trials), Gainesville (6 trials), Winter Park (6 trials), Maitland (5 trials), Miami Lakes (4 trials), and Coral Gables (4 trials).

As we move through May, Jacksonville's active research community continues to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare, particularly in areas like obesity, heart failure, and Alzheimer's disease.